Melanoma (Skin) Clinical Trial
Official title:
Investigation of a Behavioral Substitute for Sunbathing
RATIONALE: Understanding why sunbathers use or don't use sunless tanning products may help
doctors plan effective ways to prevent skin cancer caused by sunbathing.
PURPOSE: This phase I/II trial is studying attitudes about the use of sunless tanning
products and how well sunless tanning products work as a substitute for sunbathing in
healthy participants.
OBJECTIVES:
Primary
- Determine participants' attitudes regarding the benefits and barriers to using sunless
tanning products after having sampled them. (Phase I)
- Determine participants' opinions, suggestions, and preferences regarding use of sunless
tanning products. (Phase I)
- Determine the validity and reliability of the Sunless Tanning Attitudes Survey.
- Determine time spent sunbathing in random beach-goers. (Phase II)
Secondary
- Determine sunburn frequency in random beach-goers. (Phase II)
- Determine the use of a sunless tanner in these participants. (Phase II)
- Determine sun protection use in these participants. (Phase II)
- Determine perceptions of sun protection, susceptibility to photoaging, benefits of
sunbathing, and severity of photoaging. (Phase II)
OUTLINE: This is an open-label phase I study followed by a pilot, randomized, controlled
phase II study.
- Phase I (focus group): Participants complete the Sunless Tanning Attitudes (STA)
survey, Sun Behavior (SB) survey, and the Decisional Balance for Sun Exposure and Sun
Protection Questionnaire. Participants who have used a sunless tanner in the past also
complete the Sunless Tanner Users (STU) survey. Participants receive sunless tanning
lotion and instructions for its use. Participants are instructed to use the sunless
tanner for 2 weeks (≥ 3 applications). Participants then complete the STA, SB, and STU
surveys and participate in a focus group.
- Phase II:Participants are stratified by beach location and randomized to 1 of 2
intervention arms.
- Arm I: Participants complete surveys as in phase I. Photographs are taken of the
participants and they then receive sunscreen lotion and sunless tanning lotion and
instructions and benefits for using both. Participants also receive an educational
pamphlet regarding skin cancer.
- Arm II: Participants complete surveys as in phase I. A souvenir photograph is
taken of the participants and they then receive product samples that are
irrelevant to skin cancer risk reduction (e.g., skin moisturizer, hair gel,
chewing gum). Participants also receive educational materials at the completion of
the study.
In both arms, participants complete surveys again at 2 and 12 months.
PROJECTED ACCRUAL: A total of 330 participants will be accrued for this study.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04062032 -
Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma
|
Phase 2 | |
Completed |
NCT03620019 -
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
|
Phase 2 | |
Active, not recruiting |
NCT03291002 -
Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC
|
Phase 1 | |
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Completed |
NCT00962845 -
Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery
|
Early Phase 1 | |
Completed |
NCT00324623 -
Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma
|
Phase 1 | |
Completed |
NCT00104845 -
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
|
Phase 1 | |
Completed |
NCT00096382 -
Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT00072124 -
Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma
|
Phase 3 | |
Completed |
NCT00089193 -
Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
|
Phase 2 | |
Completed |
NCT00072085 -
Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Active, not recruiting |
NCT00039234 -
Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver
|
Phase 3 | |
Completed |
NCT00042783 -
Vaccine Therapy in Treating Patients With Stage IV Melanoma
|
Phase 2 | |
Completed |
NCT00049010 -
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
|
N/A | |
Completed |
NCT00006385 -
Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT00020358 -
Vaccine Therapy in Treating Patients With Melanoma
|
Phase 2 | |
Completed |
NCT00006022 -
Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer
|
Phase 1 | |
Completed |
NCT00005610 -
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
|
Phase 2 | |
Recruiting |
NCT03767348 -
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
|
Phase 2 | |
Withdrawn |
NCT00006126 -
Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery
|
Phase 1 |